Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

66

Participants

Timeline

Start Date

October 31, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

December 31, 2009

Conditions
Depression
Interventions
DRUG

S-citalopram

Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.

BEHAVIORAL

Cognitive behavioral therapy (CBT)

Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.

PROCEDURE

TRODAT-1 single photon emission computed tomographic (SPECT) imaging

Participants' striatal dopamine transporter (DAT) levels will be measured using \[99mTc\]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.

Trial Locations (1)

19104

Depression Research Unit - University of Pennsylvania, Philadelphia

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of Pennsylvania

OTHER

NCT00655057 - Effects of Antidepressant Therapy on Brain Dopamine Transporter Activity in People With Major Depression | Biotech Hunter | Biotech Hunter